Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2025年1月7日 - 9:30PM
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic
medicine company dedicated to pioneering treatments for genetically
defined cardiovascular diseases, today announced that R. Nolan
Townsend, Chief Executive Officer of Lexeo Therapeutics, will
present at the 43rd Annual J.P. Morgan Healthcare Conference on
Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco,
California.
The event will be webcast live under the News & Events tab
in the Investors section of the Company’s website. A replay of the
webcast will be available on the website following the
presentation.
About Lexeo TherapeuticsLexeo Therapeutics is a
New York City-based, clinical stage genetic medicine company
dedicated to transforming healthcare by applying pioneering science
to fundamentally change how genetically defined cardiovascular
diseases and APOE4-associated Alzheimer’s disease are treated.
Using a stepwise development approach, Lexeo is leveraging early
proof-of-concept functional and biomarker data to advance a
pipeline of cardiovascular and APOE4-associated Alzheimer’s disease
programs.
Media Response:media@lexeotx.com
Investor Response:Carlo Tanzi,
Ph.D.ctanzi@kendallir.com
Lexeo Therapeutics (NASDAQ:LXEO)
過去 株価チャート
から 12 2024 まで 1 2025
Lexeo Therapeutics (NASDAQ:LXEO)
過去 株価チャート
から 1 2024 まで 1 2025
